Drug Profile

Mesenchymal stem cell therapy for cartilage repair - Medipost

Alternative Names: Cartistem; SMUP-IA-01

Latest Information Update: 18 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medipost
Class Mesenchymal stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Marketed Osteoarthritis
No development reported Knee injuries

Most Recent Events

13 Feb 2026 MEDIPOST files an IND amendment to the US FDA to support the initiation of a phase III trial for knee osteoarthritis
13 Feb 2026 Medipost plans a phase III trial for Knee osteoarthritis in the US in the first half of 2026
14 Jan 2026 Medipost plans a phase III CARTISTEM23-01 trial for Osteoarthritis (Treatment-resistant) (NCT07339111)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com